Merck Unit, Hanmi Sign S. Korea’s First Global Co-Marketing Agreement
This article was originally published in PharmAsia News
Executive Summary
South Korea's Hanmi Pharmaceutical has reached an agreement with Merck branch MSD Korea for the country's first global co-marketing rights for a drug. Under the agreement, MSD Korea would have foreign rights to Hanmi's hypertension drug, IMD, (amlodiphine/losartan), but also is joining with Hanmi to ready an application for marketing approval to the Korea FDA. The drug combines Hanmi's API with an API of MSD Korea. (Click here for more